Classifications

• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
  • C12N9/10—Transferases (2.)
  • C12N9/1025—Acyltransferases (2.3)
  • C12N9/104—Aminoacyltransferases (2.3.2)
  • C12N9/1044—Protein-glutamine gamma-glutamyltransferase (2.3.2.13), i.e. transglutaminase or factor XIII
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
  • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
  • A61K35/14—Blood; Artificial blood
  • A61K35/16—Blood plasma; Blood serum
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
  • A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
  • A61L2/0005—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts
  • A61L2/0011—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts using physical methods
  • A61L2/0023—Heat
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
  • C07K14/745—Blood coagulation or fibrinolysis factors
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
  • C12N9/14—Hydrolases (3)
  • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
  • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
  • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
  • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
  • C12N9/6424—Serine endopeptidases (3.4.21)
  • C12N9/6443—Coagulation factor XIa (3.4.21.27)
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12Y—ENZYMES
  • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
  • C12Y304/21—Serine endopeptidases (3.4.21)
  • C12Y304/21027—Coagulation factor XIa (3.4.21.27)
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K38/00—Medicinal preparations containing peptides

Definitions

• Composition for stabilizing blood plasma during pasteurization is provided.
• the invention relates to a composition for stabilizing blood plasma during pasteurization, a method using said composition and the plasma solutions thus obtained, particularly intended for plasma replacement therapies and factors V, XI and XIII of blood coagulation.
• Whole or cryoprotein-free human plasma is still used as a replacement therapy for burn victims, severely traumatized subjects or who have undergone major surgical procedures, that is to say in all cases where patients undergo significant loss of fluids.
• REPLACEMENT SHEET may be totally ineffective on another.
• albumin can be stabilized by acetyl tryptophan and caprylate (Gellis et al. J. Clin. Invest. 27, 1948, 239-244) while these stabilizers have no effect on plasminogen.
• Thrombin can be stabilized by high concentrations of glycosides (Seegers.Arch. Biochem. 3, 1944, 363-367) while these do not protect prothrombin.
• the addition of an amino acid and a carbohydrate has given good results with Factor VIII and antithrombin III (see patent DE 29.16.711).
• European patent 0 035 204 demonstrates a stabilization of 1 ′ (X antitrypsin, of antithrombin III, of prekallikrein, of fibronectin and of Factor VIII in the presence of a polyol, the latter being only exemplified by sucrose; it indicates however that under the same conditions Factor IX and prekallikrein lose all their therapeutic activity.
• the Applicant Since the medical need still exists for total plasma, the Applicant has sought to develop a composition ensuring the simultaneous protection of the biological activity of all the factors of therapeutic interest against denaturation during pasteurization.
• the composition according to the invention consists of a mixture of sorbitol, calcium chloride, heparin and lysine. The concentrations of the different
• composition according to the invention is added to the fresh plasma or to the fresh frozen-thawed plasma or to the plasma devoid of the proteins of the cryoprecipitate, before subjecting the latter to pasteurization by heating at 60 ° C ⁇ 1 ° C for 10 hours.
• the temperature is gradually lowered to 20 ° C and the solution is subjected to dialysis to remove the sorbitol and heparin.
• the dialysis buffer is at pH 7, contains sodium citrate at a concentration between 4 and 10 mM, calcium chloride 4 mM, 0.13 M sodium chloride and lysine at a concentration of 4 g / 1.
• Dialysis pads of different composition can also be used as needed.
• the solution is then concentrated to restore the physiological dosage of plasma proteins.
• the resulting solution is subjected to sterilizing filtration, conditioned and then frozen or lyophilized.
• the invention also relates to the plasma pasteurization process which comprises the addition of the composition according to the invention to the plasma, before heating, and then the dialysis of the pasteurized plasma against the buffer as defined above.
• This process is particularly advantageous because it can be applied to large batches of plasma from several independent crops. More particularly, the pasteurization of batches of 100 to 200 liters or more makes it possible, after having carried out the appropriate checks, to guarantee consistency in the quality of the batches.
• batches of plasma pasteurized by the process according to the invention can also serve as
• REPLACEMENT SHEET substitute products for patients with deficiencies in coagulation factors for which there are no purified concentrates such as Factor V, Factor XI and Factor XIII.
• the invention therefore therefore also relates to pasteurized plasma solutions obtained by the process according to the invention and more particularly intended - on the one hand for the treatment of deficiencies in Factors V, XI and XIII of coagulation and - on the other hand for therapy of replacement requiring whole plasma or cryoprecipitate supernatant.
• EXAMPLE Two liters of thawed plasma are added to heparin (1000 ⁇ ) of lysine (8 g) and calcium chloride 220 g. These two products are added in the form of powdered salts, the plasma being subjected to gentle stirring. Then, 1200 g of undissolved sorbitol are poured gradually.
• Pasteurization is carried out in a 5 liter container by heating at 60 ° C for 10 hours using either a water bath or in a thermostatically controlled tank.
• sorbitol and heparin are eliminated by dialysis with an artificial kidney or an ultrafiltration system such as the Pellicon (M) system on cassettes, using a citrate buffer containing lysine at a concentration of 4 g / 1, 4 mM CaC12 and 0.13 M NaCl.
• Dialysis can be followed by concentration on the same material to bring the coagulation factor levels to almost 1 ⁇ / ml as in good quality therapeutic plasma. .
• the material is dialyzed at an osmolarity of 370 mosmol / 1 and a pH of 7.
• the product is then sterile filtered, for example on a Millipack (M) 40 filter (Millipore) with 0.22 ⁇ m pores.
• the material is distributed in plastic bags for freezing or in vials for freeze-drying.
• REPLACEMENT SHEET Stabilization of the plasma during pasteurization and ultrafiltration by adding calcium, heparin and lysine makes it possible to obtain the following yields, compared with (noted below vs) a control containing only lysine and sorbitol.
• bovine FVII / coagulating FVII ratio is 0.95 vs 1.09 for the control.
• the stability tested by following the activity of FVIII after 24 hours of conservation of the product in the liquid state and at room temperature, is not altered compared to the control (recovery of 100% of the activity). This is in support of a PKA rate ⁇ 2% for pasteurized and control products.
• controls on the rat by intravenous injection of plasma thus pasteurized, indicate the absence of a hypotensive effect and do not reveal any modification of the heart rate.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Engineering & Computer Science (AREA)
• Organic Chemistry (AREA)
• Zoology (AREA)
• Genetics & Genomics (AREA)
• General Health & Medical Sciences (AREA)
• Medicinal Chemistry (AREA)
• Wood Science & Technology (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Biomedical Technology (AREA)
• Molecular Biology (AREA)
• Biochemistry (AREA)
• General Engineering & Computer Science (AREA)
• Hematology (AREA)
• Biotechnology (AREA)
• Microbiology (AREA)
• Epidemiology (AREA)
• Cell Biology (AREA)
• Animal Behavior & Ethology (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Pharmacology & Pharmacy (AREA)
• Biophysics (AREA)
• Gastroenterology & Hepatology (AREA)
• Developmental Biology & Embryology (AREA)
• Immunology (AREA)
• Virology (AREA)
• Toxicology (AREA)
• Medicines Containing Material From Animals Or Micro-Organisms (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• External Artificial Organs (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
• Materials For Medical Uses (AREA)
• Medicinal Preparation (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Priority Applications (10)

Applications Claiming Priority (2)

Publications (1)

Family

ID=9398269

Family Applications (1)

Country Status (22)

Cited By (3)

Families Citing this family (2)

Citations (4)

Family Cites Families (2)

• 1990
  • 1990-07-03 FR FR9008375A patent/FR2664165B1/fr not_active Expired - Lifetime
• 1991
  • 1991-06-20 CA CA002065284A patent/CA2065284A1/fr not_active Abandoned
  • 1991-06-20 DK DK91912152.5T patent/DK0497929T3/da active
  • 1991-06-20 HU HU92701A patent/HU208404B/hu unknown
  • 1991-06-20 PL PL91294037A patent/PL166579B1/pl unknown
  • 1991-06-20 EP EP91912152A patent/EP0497929B1/fr not_active Expired - Lifetime
  • 1991-06-20 AU AU80629/91A patent/AU8062991A/en not_active Abandoned
  • 1991-06-20 RU SU915011827A patent/RU2045902C1/ru active
  • 1991-06-20 SK SK579-92A patent/SK279031B6/sk not_active IP Right Cessation
  • 1991-06-20 AT AT91912152T patent/ATE135238T1/de not_active IP Right Cessation
  • 1991-06-20 DE DE69117920T patent/DE69117920T2/de not_active Expired - Lifetime
  • 1991-06-20 JP JP03511111A patent/JP3132828B2/ja not_active Expired - Lifetime
  • 1991-06-20 WO PCT/FR1991/000493 patent/WO1992000767A1/fr active IP Right Grant
  • 1991-06-20 ES ES91912152T patent/ES2084821T3/es not_active Expired - Lifetime
  • 1991-06-24 ZA ZA914848A patent/ZA914848B/xx unknown
  • 1991-07-02 PT PT98190A patent/PT98190B/pt not_active IP Right Cessation
• 1992
  • 1992-02-27 CZ CS92579A patent/CZ281431B6/cs not_active IP Right Cessation
  • 1992-02-28 NO NO920791A patent/NO179127C/no not_active IP Right Cessation
  • 1992-03-02 FI FI920934A patent/FI96918C/sv not_active IP Right Cessation
  • 1992-12-24 LV LVP-92-497A patent/LV10384B/xx unknown
  • 1992-12-29 LT LTIP264A patent/LT3419B/lt not_active IP Right Cessation
• 1996
  • 1996-05-27 GR GR960401411T patent/GR3020048T3/el unknown

Patent Citations (4)

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events